"Dactinomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
| Descriptor ID |
D003609
|
| MeSH Number(s) |
D03.633.300.200 D04.345.566.252 D12.644.641.252
|
| Concept/Terms |
Cosmegen- Cosmegen
- Cosmegen Lyovac
- Lyovac, Cosmegen
- Lyovac-Cosmegen
- Lyovac Cosmegen
- LyovacCosmegen
|
Below are MeSH descriptors whose meaning is more general than "Dactinomycin".
Below are MeSH descriptors whose meaning is more specific than "Dactinomycin".
This graph shows the total number of publications written about "Dactinomycin" by people in this website by year, and whether "Dactinomycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dactinomycin" by people in Profiles.
-
Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2022 Jan 15; 128(2):317-325.
-
Congenital spindle cell rhabdomyosarcoma. Pediatr Blood Cancer. 2019 11; 66(11):e27935.
-
Inpatient versus outpatient vincristine, dactinomycin, and cyclophosphamide for pediatric cancers: Quality and cost implications. Pediatr Blood Cancer. 2015 Nov; 62(11):1925-8.
-
p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy. Br J Cancer. 2013 Dec 10; 109(12):2954-8.
-
Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med. 2012 Jul 15; 53(2):289-96.
-
A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol. 2012 May; 19(5):1637-43.
-
Laparoscopic nephron-sparing resection of synchronous Wilms tumors in a case of hyperplastic perilobar nephroblastomatosis. J Pediatr Surg. 2011 May; 46(5):983-8.
-
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010 Nov; 1(7):639-650.
-
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk? Pediatr Blood Cancer. 2009 Dec 15; 53(7):1332-3.
-
Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy. Pediatr Blood Cancer. 2009 Jul; 53(1):23-7.